Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
Public ClinicalTrials.gov record NCT00318370. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Study identification
- NCT ID
- NCT00318370
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Morphotek
- Industry
- Enrollment
- 58 participants
Conditions and interventions
Interventions
- Farletuzumab Drug
- Chemo Plus Far Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2006
- Primary completion
- Jan 31, 2010
- Completion
- May 31, 2010
- Last update posted
- Sep 8, 2015
2006 – 2010
United States locations
- U.S. sites
- 18
- U.S. states
- 11
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sharp HealthCare | San Diego | California | 92123 | — |
| St. Vincent Gynecologic Oncology | Indianapolis | Indiana | 46260 | — |
| Hematology and Oncology Specialists, LLC | Covington | Louisiana | 70433 | — |
| Jayne Gurtler, M.D. | Metairie | Louisiana | 70006 | — |
| Hematology and Oncology Specialists, LLC | Metarie | Louisiana | 70006 | — |
| Johns Hopkins University | Baltimore | Maryland | 21231 | — |
| The Center for Cancer and Hematologic Disease | Cherry Hill | New Jersey | 08003 | — |
| The Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| Cooper University Hospital | Voorhees Township | New Jersey | 08043 | — |
| New York Oncology Hematology | Albany | New York | 12206 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Lehigh Valley Women's Cancer Center | Allentown | Pennsylvania | 18104 | — |
| Gynecology Oncology Research & Development | Greenville | South Carolina | 29601 | — |
| Mary Crowley Medical Research Center | Dallas | Texas | 75246 | — |
| South Texas Oncology & Hematology | San Antonio | Texas | 78229 | — |
| Tyler Cancer Center | Tyler | Texas | 75702 | — |
| Northern Virginia Pelvic Surgery Associates | Annandale | Virginia | 22003 | — |
| Peninsula Cancer Center | Newport News | Virginia | 23601 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00318370, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 8, 2015 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00318370 live on ClinicalTrials.gov.